Pneumocystosis
Pneumocystosis often stands out as an infection predominantly associated with pneumonia, which primarily afflicts individuals with advanced human immunodeficiency virus (HIV). Our company works on diagnosing and treating research of rare diseases, which can help you unravel its pathogenesis and cultivate groundbreaking therapies for pneumocystosis.
Introduction to Pneumocystosis
Pneumocystis jirovecii precipitates pneumocystosis, which is a fungus that takes advantage of weakened immune systems. Most susceptible to this opportunistic infection are HIV/AIDS individuals, organ transplant recipients, and individuals receiving chemotherapy. Manifesting as a subacute onset of dyspnea, a non-sputum cough, and mild fevers.
Fig.1 Pneumocystis infection chain. (Xue, T., et al., 2023)Pathogenesis of Pneumocystosis
Pneumocystis jirovecii, a pathogen responsible for pneumocystis disease, is known to spread through the inhalation of airborne droplets. Upon entering the lungs and attaching to the alveoli, pneumocystis jirovecii has the potential to interact with the components of pulmonary surfactant, leading to the destruction of the alveolar epithelial cells and the alveolar-capillary barrier. This process triggers an inflammatory response, which, if excessive, can lead to severe lung injury and impaired gas exchange. Consequently, hypoxia and respiratory failure may occur.
Diagnostics Development of Pneumocystosis
Traditional methods of detection, such as serological and secretion tests have been implicated in instances of suboptimal sensitivity and specificity, thereby developing the need for newer, more accurate modes of detection, to usher in an era of personalized, precision therapeutics.
- Metagenomic next generation sequencing
- Loop-mediated isothermal amplification
- Polymerase chain reaction
- Flow cytometry
- Antibody assays
- Antigen and biomarker assays
Therapeutics of Pneumocystosis
Small Molecule Drugs Therapy
Trimethoprim-sulfamethoxazole (TMP-SMX) is the regimens primarily of pneumocystosis. The development of novel drugs such as sulfasalazine and caspofungin therapeutics can exert immunomodulatory and anti-inflammatory effects, thus mitigating lung inflammation and promoting efficient fungal clearance.
Monoclonal Antibodies Therapy
Emerging as a promising new therapeutic approach is the use of monoclonal antibodies for single antibody therapy. Monoclonal antibody mAb M5E12 or anti-PD-1 antibody therapy can amplify the phagocytosis capacity of alveolar macrophages, thereby enhancing the clearance of pathogens and improving individual outcomes.
Our Services
Our company with a team of seasoned professionals exhibits exceptional acumen in animal model creation and therapeutic development, catering to a host of research demands. Which can support you to enhance your understanding of pneumocystosis and facilitate the development of pioneering therapies.
Platforms of Pneumocystosis Therapy Development
Animal Models of Pneumocystosis
Animal models are crucial for understanding the pathogenesis of the disease and for developing therapeutic interventions. Our company can provide a pneumocystosis animal model to support your ongoing and upcoming research, exposing the idiosyncrasies of the disease.
| Chemical-induced Models | ||
|---|---|---|
| Animal oral or injection of corticosteroids such as dexamethasone, cortisone acetate, methylprednisolone, and other drugs can induce sufficient immune dysfunction, which is conducive to the development of pneumocystis pneumonia. | ||
| Optional Models |
|
|
|
||
| Genetically Engineered Models | ||
| The immunodeficiency transgenic model provides support for pneumocystis infection, which is mainly divided into general immunodeficiency and transgenic models for specific genes related to host response. | ||
| Optional Models |
|
|
|
||
| Optional Species | Mice, Rats, Rabbit, Non-Human Primates, Others | |
Capitalizing on our substantial experience and advanced technology, we strive to provide a platform that supports your research of the in-depth exploration of the pathogenesis of pneumocystosis and supports your pharmacokinetics analysis and drug safety evaluation. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Bateman, Marjorie et al. "Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches." Medical mycology 58.8 (2020): 1015-1028.
- Chesnay, Adélaïde et al. "Pneumocystis Pneumonia: Pitfalls and Hindrances to Establishing a Reliable Animal Model." Journal of fungi (Basel, Switzerland) 8.2 (2022): 129.
- Xue, Ting et al. "Trends in the Epidemiology of Pneumocystis Pneumonia in Immunocompromised Patients without HIV Infection." Journal of fungi (Basel, Switzerland) 9.8 (2023): 812.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.